心脉隆注射液联合西药应用于冠心病心力衰竭患者治疗的临床疗效及血浆NT-proBNP的影响

Clinical efficacy of Xinmailong Injection combined with western medicine in the treatment of patients with coronary heart disease and heart failure and the effect of plasma NT-proBNP

目的对于冠心病心力衰竭患者,探究实施西药+心脉隆注射液共同治疗对血浆NT-proBNP以及临床疗效的影响。方法本次研究随机挑选1年内(2019年2月至2020年2月)到院治疗的冠心病心力衰竭患者70例进行研究,根据实施治疗方式不同将其分为35例基础组和35例试验组。将西药用于治疗35例基础组患者,将西药+心脉隆注射液用于治疗35例试验组患者。分别对2组患者治疗前后血浆NT-proBNP水平变化情况以及临床疗效进行比对。结果治疗后与试验组相对比,参照组患者血浆NT-proBNP水平显著偏高(P<0.05);治疗后与试验组相对比,参照组患者总有效率显著偏低(P<0.05)。结论将血浆NT-proBNP水平联合用于治疗临床收治的冠心病心力衰竭患者,可显著提升整体临床疗效,同时改善患者血浆NT-proBNP水平。

Objective To explore the effect of western medicine plus Xinmailong Injection on plasma NT-proBNP and clinical efficacy in patients with coronary heart disease and heart failure.Methods This study randomly selected 70 patients with coronary heart disease and heart failure who came to hospital for treatment within one year(February 2019 to February 2020)and divided them into 35 basic groups and 35 experimental groups according to different treatment methods.Western medicine was used to treat 35 patients in the basic group and western medicine+Xinmailong injection was used to treat 35 patients in the experimental group.The changes of plasma NT-proBNP level and clinical efficacy of the two groups were compared before and after treatment respectively.Results Compared with the experimental group,the plasma NT-proBNP level in the reference group was significantly higher(P<0.05).Compared with the experimental group after treatment,the total effective rate in the reference group was significantly lower(P<0.05).Conclusion The combination of plasma NT-proBNP level and clinical treatment for patients with coronary heart disease and heart failure can significantly improve the overall clinical efficacy and improve the plasma NT-proBNP level of patients.